Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial

被引：11

作者：

Furuhashi, Kazuki ^{[1
,2
]}

Fujisawa, Tomoyuki ^{[1
]}

Hashimoto, Dai ^{[3
]}

Kamiya, Yousuke ^{[1
]}

Yasui, Hideki ^{[1
]}

Karayama, Masato ^{[1
]}

Suzuki, Yuzo ^{[1
]}

Hozumi, Hironao ^{[1
]}

Enomoto, Noriyuki ^{[1
]}

Nakamura, Yutaro ^{[1
]}

Inui, Naoki ^{[1
,4
]}

Suda, Takafumi ^{[1
]}

机构：

[1] Hamamatsu Univ, Dept Internal Med, Div 2, Sch Med, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[2] Hamamatsu Univ, Dept Lab Med, Sch Med, Hamamatsu, Shizuoka, Japan

[3] Seirei Hamamatsu Gen Hosp, Dept Resp Med, Hamamatsu, Shizuoka, Japan

[4] Hamamatsu Univ, Dept Clin Pharmacol & Therapeut, Sch Med, Hamamatsu, Shizuoka, Japan

来源：

JOURNAL OF ASTHMA AND ALLERGY | 2019年 / 12卷

关键词：

fluticasone furoate/vilanterol; budesonide/formoterol; stable asthma; randomized crossover trial; inhalation adherence barriers; PERSISTENT ASTHMA; ADHERENCE STARTS; OPEN-LABEL; FUROATE; VILANTEROL; EFFICACY; VALIDITY; SAFETY; RELIABILITY; QUESTIONNAIRE;

D O I：

10.2147/JAA.S223093

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Introduction: Fluticasone furoate (FF)/vilanterol (VI) dry powder inhaler (DPI) is the only once-daily maintenance inhaled corticosteroid (ICS)/long-acting (32 adrenergic agonist (LABA) combination for asthma. We aimed to compare the clinical effects of once-daily FF/VI and twice-daily budesonide (BUD)/formoterol (FM) DPI in patients with controlled stable asthma. Methods: We performed a randomized crossover trial in which stable asthmatic patients controlled on ICS/LABA received 8 weeks of FF/VI (100/25 mu g 1 puff once-daily) or BUD/FM (160/4.5 mu g 2 puffs twice-daily) DPI treatment. After a 4-8-week washout period, patients received another crossover treatment for 8 weeks. We assessed pulmonary function, the 5-item version asthma control questionnaire (ACQ5), the asthma control test (ACT), and fractional exhaled nitric oxide (FeNO) at baseline and after 8 weeks of treatment (week 8). As the primary outcome was change in force expiratory volume in 1 s (FEV1) between baseline and week 8, we evaluated the incidence of asthma exacerbation and adherence barrier questionnaire (Ask-12) at week 8. Results: Twenty-three patients were initially enrolled in this study; however, one patient had to be excluded. The FF/VI DPI treatment group showed a similar magnitude of change in FEV1 between baseline and week 8 as the BUD/FM DPI treatment group. In addition, there were no significant differences in pulmonary function tests, ACQ5 scores, ACT scores, and FeNO between baseline and week 8 in both groups. Although the incidence of exacerbation did not differ between groups, the Ask-12 score in the FF/VI DPI group was significantly lower than that in the BUD/FM DPI group. Conclusions: The present study indicates that once-daily FF/VI DPI is not inferior to twice-daily BUD/FM DPI in clinical effect and more likely to improve inconvenience and forgetfulness in inhalation adherence barriers for stable asthma control therapy. Once-daily FF/VI DPI may be an effective alternative for asthma maintenance treatment.

引用

页码：253 / 261

页数：9

共 34 条

[11]

Dwan K, 2016, COCHRANE DB SYST REV, V9

[12] Inhaler technique and asthma: Feasability and acceptability of training by pharmacists [J].